Antiangiogenic Strategies for the Treatment of Gliomas

摘要: Malignant gliomas (glioblastoma and anaplastic forms of astrocytoma oligodendroglioma) are highly vascularized tumors and, therefore, constitute ideal targets for new antiangiogenic treatments. Angiogenesis is a complex biologic process, involving multitude different molecular drivers signaling pathways. The vascular endothelial growth factor (VEGF) pathways appear to play key role in this targeting such has emerged as one the most efficient strategies. To date, best studied these drugs been anti-VEGF monoclonal antibody, bevacizumab. In recurrent malignant gliomas, drug achieves high response rates seems prolong progression-free survival. However, similar other solid tumors, magnitude survival benefit less obvious, patients eventually progress after an initial clinical benefit. chapter, we seek recapitulate development antiangiogenesis treatment from mechanisms challenges evaluation setting.